文献速递瓣膜外科

再次主动脉瓣置换术风险下降:对瓣膜选择与经导管治疗的意义

The decreasing risk of reoperative aortic valve replacement: Implications for valve choice and transcatheter therapy.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-03-16

该研究比较了再次主动脉瓣置换术与初次孤立主动脉瓣置换术的风险。1980年1月至2017年7月共7037例非急诊孤立主动脉瓣置换术,其中再次手术753例,初次手术6284例,倾向性评分匹配46个术前变量后得到581对患者。匹配后再次手术组主动脉阻断时间和体外循环时间更长,输血和因出血/填塞再次手术更常见,但医院死亡率、卒中、深部胸骨伤口感染和新发肾透析相似;再次手术医院死亡率从1985年3.4%降至2011年1.3%。

要点

  • 再次主动脉瓣置换术的死亡率和并发症风险已下降,目前与初次孤立主动脉瓣置换术相似。
  • 匹配后再次手术组主动脉阻断时间中位数63 vs 52分钟,体外循环时间中位数88 vs 67分钟,均更长。
  • 再次手术组输血67% vs 36%,因出血/填塞再次手术6.4% vs 3.1%,均更常见。

核心结论

  • 再次主动脉瓣置换术后死亡率和并发症风险已下降,目前与初次孤立主动脉瓣置换术相似。
  • 瓣膜选择和外科主动脉瓣置换术与经导管主动脉瓣置换术的决策应基于终身疾病管理,而非避免再次手术。

研究设计与样本

  • 回顾性分析1980年1月至2017月7月共7037例非急诊孤立主动脉瓣置换术患者,其中再次手术753例,初次孤立手术6284例。
  • 两组按46个术前变量进行倾向性评分匹配,得到581对患者比较结局。

主要发现

  • 匹配后再次手术组主动脉阻断时间中位数63 vs 52分钟(P < .0001),体外循环时间中位数88 vs 67分钟(P < .0001),术后住院时间中位数7.1 vs 6.9天(P = .003),均长于初次孤立手术组。
  • 再次手术组医院死亡率从1985年3.4%降至2011年1.3%,与初次孤立手术相似;卒中、深部胸骨伤口感染和新发肾透析发生率相似。
  • 再次手术组输血67% vs 36%(P < .0001),因出血/填塞再次手术6.4% vs 3.1%(P = .009),均高于初次孤立手术组。
  • 再次手术组1、5、10、20年生存率分别为94%、82%、64%、33%,择期初次孤立手术组分别为95%、86%、72%、46%。

临床怎么用

  • 作者认为,瓣膜选择和外科主动脉瓣置换术与经导管主动脉瓣置换术的决策应基于终身疾病管理,而非避免再次手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Increasing use of bioprostheses for surgical aortic valve replacement (SAVR) in younger patients, together with wider use of transcatheter aortic valve replacement, necessitates understanding risks associated with surgical valve reintervention. Therefore, we sought to identify risks of reoperative SAVR compared with those of primary isolated SAVR. METHODS: From January 1980 to July 2017, 7037 patients underwent nonemergency isolated SAVR, with 753 reoperations and 6284 primary isolated operations. These 2 groups were propensity score-matched on 46 preoperative variables, yielding 581 patient pairs for comparing outcomes. RESULTS: Among propensity score-matched patients, aortic clamp time (median 63 vs 52 minutes; P < .0001), cardiopulmonary bypass time (median 88 vs 67 minutes; P < .0001), and postoperative stay (median 7.1 vs 6.9 days; P = .003) were longer for reoperative SAVR than primary isolated SAVR. Hospital mortality after reoperative SAVR decreased from 3.4% in 1985 to 1.3% in 2011, similar to that of primary isolated SAVR. Occurrence of stroke, deep sternal wound infection, and new renal dialysis was similar. Blood transfusion (67% vs 36%; P < .0001) and reoperations for bleeding/tamponade (6.4% vs 3.1%; P = .009) were more common after reoperative SAVR. Survival at 1, 5, 10, and 20 years was 94%, 82%, 64%, and 33% after reoperative SAVR and 95%, 86%, 72%, and 46% after elective primary isolated SAVR. CONCLUSIONS: Risk of mortality and morbidity after reoperative SAVR has declined and is now similar to that of primary isolated SAVR. Decisions regarding prosthesis choice and SAVR versus transcatheter aortic valve replacement should be made in the context of lifelong disease management rather than avoidance of reoperation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mahboubi R, Kakavand M, Soltesz EG, et al. The decreasing risk of reoperative aortic valve replacement: Implications for valve choice and transcatheter therapy. J Thorac Cardiovasc Surg. 2022. PMID: 35397951. doi:10.1016/j.jtcvs.2022.02.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。